Atlas Venture 2023 Year In Review
LifeSciVC
NOVEMBER 17, 2023
2023 couldn’t end fast enough for most of us in biopharma; its been a tough year in the capital markets, and the industry is facing it’s fair share of headwinds. We then shift to the venture ecosystem and the broader capital markets, highlighting the parallels with twenty years ago, post the genomics bubble in 2002-2003.
Let's personalize your content